TFB Advisors LLC Trims Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

TFB Advisors LLC cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,262 shares of the biotechnology company’s stock after selling 29 shares during the quarter. TFB Advisors LLC’s holdings in United Therapeutics were worth $798,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of UTHR. SG Americas Securities LLC boosted its stake in United Therapeutics by 66.1% in the third quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock valued at $535,000 after acquiring an additional 594 shares in the last quarter. CWM LLC boosted its stake in United Therapeutics by 108.3% in the third quarter. CWM LLC now owns 4,006 shares of the biotechnology company’s stock valued at $1,436,000 after acquiring an additional 2,083 shares in the last quarter. Ritholtz Wealth Management boosted its stake in United Therapeutics by 14.3% in the third quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 105 shares in the last quarter. CHICAGO TRUST Co NA acquired a new stake in United Therapeutics in the third quarter valued at approximately $204,000. Finally, Creative Planning boosted its stake in United Therapeutics by 8.9% in the third quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock valued at $1,410,000 after acquiring an additional 322 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on UTHR. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $382.08.

United Therapeutics Stock Up 2.2 %

Shares of United Therapeutics stock opened at $353.31 on Wednesday. United Therapeutics Co. has a fifty-two week low of $210.64 and a fifty-two week high of $417.82. The business’s fifty day moving average is $362.06 and its two-hundred day moving average is $358.24. The firm has a market cap of $15.78 billion, a PE ratio of 15.52, a P/E/G ratio of 0.92 and a beta of 0.57.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,743,122.70. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 121,864 shares of company stock valued at $44,516,965 over the last quarter. Company insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.